ea0038p208 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2015
Brighton Cheryl A
, Rievaj Juraj
, Kuhre Rune E
, Glass Leslie L
, Holst Jens J
, Gribble Fiona M
, Reimann Frank
Background: Glucagon-like peptide 1 (GLP-1) is an incretin hormone released from enteroendocrine L-cells in the gut. GLP-1 analogues and dipeptidyl-peptidase-4 inhibitors are currently used to treat type-2 diabetes. A greater understanding of the mechanisms underlying the release of GLP-1 may facilitate the development of therapeutics to stimulate the release of endogenous GLP-1. Bile acids have been shown to induce GLP-1 release via the G protein-coupled bile acid receptor 1 ...